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ABSTRACT
Background: Human papillomavirus (HPV) and HIV are each responsible for a considerable
burden of disease. Interactions between these infections pose substantial public health
challenges, especially where HIV prevalence is high and HPV vaccine coverage low.
Methods: Between July 2005 and January 2006, a cross-sectional community-based survey
in Mombasa, Kenya, enrolled female sex workers using snowball sampling. After interview
and a gynaecological examination, blood and cervical cytology samples were taken.
Quantitative real-time PCR detected HPV types and viral load measures. Prevalence of high-
risk HPV was compared between HIV-infected and -uninfected women, and in women with
abnormal cervical cytology, measured using conventional Pap smears.
Results: Median age of the 820 participants was 28 years (inter-quartile range [IQR]=24–36
years). One third of women were HIV infected (283/803; 35.2%) and these women were y
more likely to have abnormal cervical cytology than HIV-negative women (27%, 73/269,
versus 8%, 42/503; P<0.001). Of HIV-infected women, 73.3% had high-risk HPV (200/273)
and 35.5% had HPV 16 and/or 18 (97/273). Corresponding figures for HIV-negative women
were 45.5% (229/503) and 15.7% (79/503). After adjusting for age, number of children and
condom use, high-risk HPV was 3.6 fold more common in HIV-infected women (95%CI=2.6-
5.1). Prevalence of all 15 of the high-risk HPV types measured was higher among HIV-
infected women, between 1.4 and 5.5 fold. Median total HPV viral load was 881 copies/cell in
HIV-infected women (IQR=33-12,110 copies/cell) and 48 copies/cell in HIV-uninfected women
(IQR=6-756 copies/cell; P<0.001). HPV 16 and/or HPV 18 were identified in 42.7% of LSIL
(32/75) and 42.3% of HSIL (11/26) lesions (P=0.98). High-risk HPV types other than 16 and
18 were common in LSIL (74.7%; 56/75) and HSIL (84.6%; 22/26); even higher among HIV-
infected women.
Conclusions: HIV-infected sex workers had almost four-fold higher prevalence of high-risk
HPV, raised viral load and more precancerous lesions. HPV 16 and HPV 18, preventable with
current vaccines, were associated with cervical disease, though other high-risk types were
commoner. HIV-infected sex workers likely contribute disproportionately to HPV transmission
dynamics in the general population. Current efforts to prevent HIV and HPV are inadequate.
New interventions are required and improved implementation of existing strategies.
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BACKGROUND
Human papillomavirus (HPV) is the most common sexually transmitted infection (STI)
worldwide. It is the pre-eminent etiologic agent of cervical cancer, the second most common
cancer among women [1]. Over 100 HPV types have been identified, about 20 of which are
termed high-risk types, because of their propensity to disrupt control of normal cell-cycles and
thereby foment the development of cervical malignancy [2]. In addition to cervical neoplasia,
HPV is also causally associated with anogenital, oropharyngeal and some skin cancers [3, 4].
HIV, another STI with extensive public health impact [5], shares many common behavioural
risk factors with HPV and the infections interact in important ways. Female sex workers (FSW)
have a particularly high risk for both HIV and HPV infection, and the interactions between
these infections are especially pronounced in this population group [6-8].
Women with HIV infection commonly have a broader range of HPV genotypes, often with
multiple concurrent HPV infections [9]. HIV disease influences the natural history of HPV by
increasing the likelihood of persistent infection and virulence, and hastening the time-course
of HPV disease [10]. Thus, compared with HIV-negative women, HIV-positive women are
more likely to progress to cervical cancer, have a worse prognosis and a higher risk of
recurrence [11-13]. It is also important to note that the interplay between HIV and HPV
infection, and the consequences thereof are influenced by other factors such as age, sexual
practices and socio-economic characteristics of women [14-16].
Besides the effects of HIV on the natural history of HPV infection, it is possible that HIV affects
the transmissibility of HPV, and even possibly vice versa [17-19]. Causality, and the potential
bidirectional nature thereof, cannot yet be definitively determined from available, mostly cross-
sectional evidence. It remains plausible, however, that enhanced friability and the recruitment
of CD4 and dendritic cells with HPV infection increases susceptibility to HIV acquisition in a
manner similar to other genital tract infections such as Neisseria gonorrhoea.
The HPV vaccine, including high-risk HPV types 16 and 18, is effective in reducing HPV
infection and HPV-related disease in women, and potentially in men [20]. These vaccines are
increasingly becoming available in resource-constrained settings [21], which carry the
overwhelming burden of HPV disease. Additional information about the prevalence of high-risk
HPV types and their relative contribution to cervical disease in this setting would assist in
planning for vaccine implementation and future development. This study assesses the
prevalence of high-risk HPV types and HIV among FSW in Mombasa, Kenya, and the
associations between these infections and with other demographic and behavioural variables.
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Additionally, the complex inter-relationships between type-specific HPV viral load, HIV
infection and cervical cytology are evaluated.
METHODS
Setting and population
Mombasa, in Kenya’s Coast province, is a major economic centre in the region, with important
tourism, port, rail and industrial enterprises, as well as a large FSW population. Sex workers in
Mombasa are working either full- or part-time from bars, hotels, streets or from their homes
[22, 23]. About a third are involved in other small businesses, including selling foodstuffs,
vegetables and, in some areas, local brew on the roadside [23]. Commonly the clients of sex
workers are employed at local factories or are matatu (minibus taxi) touts or drivers.
Study Design
Between July 2005 and January 2006, 820 FSW from Chaani and Kisauni divisions of
Mombasa were enrolled in a community-based, cross-sectional survey. FSW were recruited
using snowball sampling, a method appropriate for locating difficult-to-reach populations,
particularly those with stigmatized behaviours or professions [24]. Full details of study
methodology are provided elsewhere [23]. In brief, initial respondents were identified from
bars, guest houses and the street, with subsequent participants recruited using snowball
sampling. To limit the potential for friendship bias, we restricted the maximum number of
women recruited through one participant to 10. Eligible participants were self-reported FSW,
older than 16 years and working within Kisauni or Chaani. For this study, sex workers were
defined as any woman who reported having received money or gifts in exchange for sex in the
past year. The Kenyatta National Hospital Ethics and Review Committee reviewed and
provided approval for the study procedures.
Study procedures
In the two study areas, an existing drop-in centre for FSW and a municipality run health centre
were modified to include clinical examination areas and related research facilities. Here staff
obtained written informed consent, collected demographic and behavioural data using
structured questionnaires, and offered HIV counselling and same-day testing. Blood plasma
samples were taken and a gynaecological examination was done with speculum insertion, and
collection of endocervical and high vaginal swabs.
Cervical samples were collected using a cervix brush (Cervex-brush®, Rovers®, Oss, The
Netherlands) and cervical cytology was assessed with conventional Papanicolaou (Pap)
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smears. Slides were read by a cytologist with masters level training, supervised by a
pathologist. An external cytopathologist provided quality control. The Bethesda Reporting
System was used for cytologic classification [25]. The cervix brush tips were preserved in a
liquid-based cytology collection medium (SurePath®, Tripath Imaging Inc., Burlington, North
Carolina, USA) and stored at 4°C until further processing.
HPV testing was done as described by Depuydt et al [26] in an accredited laboratory (ISO
certification: ISO15189). Briefly, HPV DNA was extracted from exfoliated cervical cells using
the standard proteinase K-based digestion protocol, following the manufacturer’s instructions.
Cells were incubated with proteinase K solution (100 µg/ml) for 3 hours at 55°C. DNA was
then further purified by spin column chromatography. HPV types were determined using a
series of real-time PCR reactions with specific primers and TaqMan® (Invitrogen, La Jolla,
USA) probes for high-risk HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66 and
68 [2]. Low-risk HPV types 6 and 67 were also detected.
A parallel testing algorithm was used for HIV diagnosis using rapid immunoassays: Uni-
Gold™ Recombigen® HIV (Trinity Biotech plc, Bray, Ireland) and Determine® HIV-1/2 (Abbott
Japan co Ltd, Minato-Ku, Tokyo, Japan). In the case of indeterminate results, an enzyme-
linked immunosorbent assay was used to confirm HIV status.
Where indicated, FSW received STI treatment free of charge. Women with a positive HIV test
were referred to a nearby HIV clinic where medical care and antiretroviral treatment are
provided, with no user fees. Women with abnormal cervical cytology were referred for further
management and follow-up at the provincial teaching and referral hospital (Coast Provincial
General Hospital, Mombasa) or a local municipal clinic supported by the International Centre
for Reproductive Health.
Data management and analysis
Data were double entered by separate data clerks. Following data checking and cleaning,
analysis was done using Intercooled Stata, version 10.0 (Stata Corporation, College Station,
TX, USA). The presence of any detectable viral load for specific HPV types was considered
diagnostic for infection with that specific type. Chi-square tests were used to detect
differences in HPV prevalence in women with and without HIV infection. For each HPV type,
the Mann-Whitney U test was used to compare the HPV viral load of HIV infected and
uninfected women who had ≥ 1 HPV copy/cell. Total HPV viral load was also calculated for
each woman (the sum of the viral load of each high-risk HPV infection). To account for
differences in age distribution between HIV infected and uninfected women, age-adjusted risk
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ratios are presented comparing the risk of HPV infection in these two groups. A multivariable
logistic regression model was constructed, in which the presence of any high-risk HPV
infection was the dependent variable. Fitting of the regression model was done using stepwise
backward elimination, with variables retained if their removal markedly altered model
parameters [27]. Variables associated with high-risk HPV in univariate analysis (P<0.1) were
included in the initial model. Associations between high-risk HPV infection and abnormal
cervical cytology were also assessed.
RESULTS
Socio-demographic and sexual behaviour characteristics
The median age of the 820 enrolled FSW was 28 years (IQR=24–36 years; table 1). The vast
majority were currently single, either never been married (346/818; 42.3%) or separated
(33.0%, 270/818), divorced (13.0%, 106/818) or widowed (8.9%, 73/818). Women had a
median of two children (IQR=1–3 children).
Women obtained clients mainly at bars or nightclubs (70.7%, 580/820), though about a fifth
worked mainly from home (163/820). The median income from sex work per week was
14.3US$ (IQR=8.1-27.0US$; exchange rate of US$1=74 Kenya shillings), obtained from a
mean of 2.3 sex partners per week (standard deviation (sd)=0.7). About two thirds of women
reported consistently using a condom with clients (63.2%, 518/820), while consistent condom
use with boyfriends was reported by only 92 of 437 women who currently had a boyfriend
(21.1%).
Prevalence of HIV
A third of participants were HIV infected (283/803; 35.2%); HIV status was unknown in 17
women. Compared to HIV-negative women, infected women were a median 3 years older.
With each increase in decade of age, the odds of HIV infection increased 1.6 fold (95%CI=1.4-
2.0; P<0.001). Prevalence of HIV was lower in Muslim (25.4%, 58/228) than in other women
(39.1%, 225/575; P<0.001) and women with a shorter duration of sex work (median 4 years
[IQR=2-7] for HIV-negative women versus median 5 years [IQR=3-9] for positive women;
P=0.002). HIV prevalence was also higher in widowed women (62.9%, 44/70 compared with
32.6%, 238/731 in other women; P<0.001) and in those with a recent genital sore (42.3%,
66/156 versus 33.6%, 217/646 in women without history of genital sores; P=0.04).
Prevalence of HPV infection
7
Of the 820 participants, study samples of adequate quality were obtained from 786 women for
Pap smear assessment and from 789 women for HPV typing. More than half of FSW were
infected with high-risk HPV (55.6%; 439/789). Among these women, over half had at least two
different high-risk HPV types (54.9%; 241/439). HPV types 16 and/or 18 were detected in
22.8% of women (180/789), but more than twice as many were infected with high-risk HPV
types other than 16 and 18 (48.5%, 383/789). A quarter of women were infected with low-risk
HPV type 6 and/or 67 (194/789).
Co-infection with both HIV and high-risk HPV occurred in 25.8% (200/776) of FSW (table 2).
High-risk HPV was detected in 73.3% (200/273) of HIV-infected women versus 45.5%
(229/503) of uninfected women, with an age-adjusted risk ratio (RR) of 1.7 (95%CI RR=1.5-
1.9; P<0.001). Co-infection with two or more high-risk HPV types was more frequent among
HIV positive than negative women (48.7%, 133/273 versus 20.4%, 103/506; P<0.001). Fifteen
percent of HIV-infected FSW had four or more high-risk HPV types.
Predictors of high-risk HPV infection
Among the whole study population, age was not associated with prevalence of high-risk HPV.
However, in HIV-negative women, age effects were noted. Here, HPV prevalence decreased
with increasing age, for example, 52.1% of HIV-negative women aged 17-24 years had high-
risk HPV (88/169) while this figure was 38.6% in women older than 40 years (22/57, P=0.02;
chi-square test for trend). Similarly, a linear decrease in the prevalence of HPV 16 and/or HPV
18 was noted in HIV-negative women, from a prevalence of 40.5% (32/169) in women below
25 years to 7.6% (6/57) in women above 40 years (odds of infection decreased by 0.71 with
each increase in decade of age, 95%CI=0.52-0.96; P=0.03, chi-square test for trend). Among
women with HIV infection, the prevalence of HPV 16 and/or HPV 18 did not vary across age
groups.
When adjusted for age, having a child and condom use, HIV status remained a predictor for
high-risk HPV infection (adjusted odds ratio [AOR]=3.6; 95%CI=2.6-5.1; P<0.001; table 3).
Having one or more children was also independently associated with high-risk HPV; these
women had a 2.0 fold higher odds of high-risk HPV (95%CI AOR=1.3-3.3; P=0.003) than
women with no children. High levels of reported condom use were not protective against high-
risk HPV infection, nor were other measures of sexual behaviour or sex work duration
associated with HPV prevalence.
Effect of HIV status on prevalence of specific high-risk HPV types
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Type-specific analysis showed that the most prevalent HPV types were similar in HIV-positive
and -negative women. In decreasing order, the most prevalent high-risk HPV types among
HIV-positive women were 52, 16, 53, 18, 35 and 66, while for HIV-negative women the order
was HPV 16, 59, 35, 52, 66 and 53 (table 2).
Compared with HIV uninfected women, prevalence of all HPV types was higher in HIV-
infected women, with the age-adjusted risk ratio a median 2.7 fold higher (IQR RR=2.1-3.7;
range of RRs=1.4-5.5). HPV 16 and/or HPV 18 infection was found in 35.5% (97/273) of HIV-
positive women and in 15.7% (79/503) of HIV-negative women (P<0.001).
HPV viral load
HIV infection was significantly associated with an elevated HPV viral load for types 16, 31, 39,
45, 51, 52, 59 and 66. For 9 of the 15 high-risk HPV types measured, the median viral load for
high-risk HPV was 5 or more times higher in HIV-positive than HIV-negative women. The total
HPV viral load was 16.9 times higher in women with HIV infection compared to uninfected
women (median 811 copies/cell versus 48 copies/cell; P<0.001).
Cervical cytology
High-risk HPV was strongly associated with abnormal cervical cytology, and was detected in
88.5% of women with HSIL (23/26) and 82.7% with LSIL (62/75). HPV type 16 and/or 18 was
detected in 42.7% of women with LSIL (32/75) and 42.3% with HSIL (11/26). However, high-
risk HPV types other than 16 and 18 were more frequent, occurring in 74.7% of LSIL (56/75)
and 84.6% of HSIL (22/26), even more so among HIV-infected women (12 of 13 women with
HSIL). High-risk HPV type 52 (907 copies/cell) and low-risk type 67 were detected in the
woman who had invasive carcinoma on cytology.
Half of women with a normal Pap smear had high-risk HPV (327/648), though high-risk HPV
was more common among HIV-infected women with normal cytology (67.4%; 130/193).
Abnormal Pap smears were also markedly more common in HIV-infected women, of whom
about 5% had HSIL (13/269) and 20% LSIL (54/269). The corresponding figures for HIV-
negative women were 2.4% (12/503) and 4.2% (21/503), with one woman having squamous
cell carcinoma. The 13 HIV-infected women with HSIL had a median of 3 high-risk HPV
infections (IQR=2-3).
Of the 51 HIV-infected women whose total HPV viral load was ≥104 copies/cell, 24 (47.1%)
had LSIL and 6 had HSIL lesions (11.8%). Only 18 HIV-negative women had a total HPV viral
load ≥104 copies/cell, of whom 4 had LSIL and 1 HSIL.
9
DISCUSSION
In this study, about one-third of female sex workers were infected with HIV and more than half
with high-risk HPV. In multivariable analysis, high-risk HPV was more than three times as
common among HIV-positive than negative women. Prevalence of high-risk HPV in the study
population is notably higher than in a meta-analysis of HIV-infected women including 20
studies, mostly from North America [28]. Though it is difficult to make direct comparisons
between studies as HPV detection methods differ, the prevalence in this study is similar to a
recent study among HIV-infected female hospital patients in Zambia [29]. Also of note, among
HIV-infected women who had normal cervical cytology, two thirds had high-risk HPV infection
in this study, twice as many as the meta-analysis of HIV-infected women [28]. Prevalence of
high-risk HPV in HIV-negative FSW in our study is similar to previous reports among sex
workers in other settings, for example, 39% in Spain [6], 43% in Mexico [30] and 48% in
Japan [8], though a study in Calcutta, India reported higher levels (63%) [7].
Simultaneous infection with multiple HPV types was more frequent in HIV-positive women.
This finding is consistent with previous reports [28], and according to Chaturvedi et al [31], is
attributable to the common mode of transmission of HPV and HIV; the inability to clear HPV
infections; as well as reactivation of latent HPV infections, the latter two occurring as a result
of immune suppression [9, 32-34]. Similar factors may underlie the concerning high levels of
HPV 16 and 18 noted in older HIV-positive women in this study. [35] Though here, a particular
ability of HPV 16 to evade immune surveillance in HIV-positive women may account for the
high levels noted in all age groups [34].
Persistent HPV infection is the main cause of cervical cancer, and since this is more common
in HIV-infected women, it makes the presence of cervical lesions in a quarter of HIV-positive
women in this study even more concerning [36]. Many previous studies, including one in
Mombasa [37], have noted a higher prevalence of HSIL among HIV-positive than HIV-
negative women [38-40].
Broadly, the distribution of high-risk HPV types were similar in HIV-infected and uninfected
women, albeit that the most common HPV types occurred in slightly differing order of
prevalence. However, the most common HPV types in our study differ from those in other
settings [28, 40]. These regional differences in HPV types might, at least partly, be attributed
to HIV and its differential effects on the natural history of specific types. However, not all
findings support this assertion [41].
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An association between parity and high-risk HPV has been noted previously, though might be
accounted for by confounding due to sexual behaviour, such as unprotected sex or age at
coital debut [6, 35, 42]. A large multicentre case-control study suggests, however, that full-
term pregnancy is a cofactor that increases the risk of progression from HPV infection to
cancer [35]. This, the authors speculate, might be due to hormonal changes in the second and
third trimester of pregnancy or to increased cervical ectopy with multiparity. Possibly, the
reduction in cervical cancer noted worldwide might be partly explained by the general global
decline in parity.
Age, as previously shown [6, 30, 43, 44], is an important predictor of HPV infection, with
younger women being more frequently infected. Again, the absence of age effects among
HIV-infected women in our study may be explained by a decreased ability to clear HPV
infection, reactivation of HPV or re-infection with HPV types previously cleared, all of which
likely occur more commonly in HIV-infected women.
Results presented here are consistent with a meta-analysis by De Vuyst et al. describing
higher median viral loads of high-risk HPV in HIV-positive women, regardless of HPV type
[45]. HPV viral load possibly correlates with the immune deficiency in these patients [10] and
with likelihood of persistent HPV infection [46]. The highest viral burdens were found with HPV
33 in HIV-positive women and HPV 56 in HIV-negative women. HPV 16 had a relatively low
viral load, though even at low viral levels has high oncogenic potential [47, 48].
Even though current HPV vaccines offer some cross-protection against several HPV types
[49], type-specific analysis of HPV data remains important for informing future HPV vaccine
development and distribution. In women attending a family planning clinic in Nairobi, Kenya,
less than 10% had HPV 16 and/or 18, and these types were present in about 40% of HSIL
lesions [50]. In our study, HPV 16 and/or HPV 18 were present in about 20% of study
participants, while still in about 40% of women with LSIL or HSIL. However, that most cervical
lesions were negative for HPV 16 and/or 18, suggests that other high-risk HPV types might
play a more important role in this context of female sex work. These types appear of particular
importance in HSIL lesions in HIV-infected women [28]. It is also possible that the specific
oncogenic HPV types that contribute to the development of cervical cancer in HIV-positive
women may differ from those in HIV-negative women [51].
It is difficult to ascertain to what degree the sample obtained through snowballing methods is
representative of the FSW population in Mombasa. Though snowball sampling is appropriate
for locating difficult-to-reach populations, as it is a non-random sampling method, selection
bias may occur. The investigators elected to have a large sample size, in an attempt to
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mitigate such effects. As a further limitation, information was missing on both HIV and high-
risk HPV types, which could introduce bias. Such bias, however, is likely minimal as the
missing information can be assumed to be non-differential in nature [52].
Patterns of HPV prevalence will likely alter the impact of prophylactic HPV vaccination [53].
The extent of this would be better understood if more information was available on the natural
history of dysplasia associated with HPV types other than 16 and 18. The study population
described here is highly suited to prospective assessment of this and related topics, given the
considerable burden on HPV disease in this population. Moreover, previous cohorts in this
study population have been feasible, with more than 90% cohort retention rates [54, 55].
Conclusion
Given the common occurrence of high-grade cervical lesions, especially in HIV-infected
women, regular HPV screening and follow-up is essential for prevention of cervical cancer.
Even though much is known about these diseases and their optimal control, current measures
to prevent HIV and HPV in this population are clearly inadequate. The lack of control of these
infections means that sex workers likely play a disproportionate role in transmission dynamics
of both infections in the general population. Additional prevention measures, especially higher
population-level coverage with HPV vaccine, are required.
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Table 1 Distribution of demographics and sexual behaviour by HIV status and presence of high-
risk HPV infection among female sex workers in Mombasa Kenya
Chi² test unless indicated. ¥ Mann-Whitney U test; † chi-square test for trend; | Student’s t test^ Infection with HPV type 16, 18,
31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66 and 68 defined as high-risk HPV infection
HIV-negative women HIV-positive women
Variable All women
No high-risk HPV High-risk HPV
P
No high-risk HPV High-risk HPV
P
Age n/N (%)
17-24
25-29
30-39
≥40
median years (IQR)¥
232/817 (28.4)
216/817 (26.4)
246/817 (30.1)
123/817 (15.1)
28 (24-36)
81/272 (29.8)
72/272 (26.5)
84/272 (30.9)
35/272 (12.9)
28 (23-35)
88/229 (38.4)
64/229 (28.0)
55/229 (24.0)
22/229 (9.6)
27 (22-32)
0.02†
0.02
13/73 (17.8)
14/73 (19.2)
28/73 (38.4)
18/73 (24.7)
32 (27-39)
38/199 (19.1)
54/199 (27.1)
68/199 (34.2)
39/199 (19.6)
30 (26-38)
0.26†
0.27
Religion n/N (%)
Catholic
Muslim
Protestant
Other
255/820 (31.1)
236/820 (28.8)
313/820 (38.2)
16/820 (2.0)
76/274 (27.7)
89/274 (32.5)
101/274 (36.9)
8/274 (2.9)
67/229 (29.3)
78/229 (34.1)
78/229 (34.1)
6/229 (2.6) 0.92
26/73 (35.6)
12/73 (16.4)
34/73 (46.6)
1/73 (1.4)
77/200 (38.5)
42/200 (21.0)
80/200 (40.0)
1/200 (0.5) 0.62
Education level n/N (%)
Never attended school
Primary school
Secondary school
Tertiary education
82/820 (10.0)
513/820 (62.6)
202/817 (24.8)
22/817 (2.7)
33/274 (12.0)
164/274 (59.9)
67/274 (24.5)
10/274 (3.7)
17/229 (7.4)
148/229 (64.6)
57/229 (24.9)
7/229 (3.1) 0.35
6/73 (8.2)
45/73 (61.6)
20/73 (27.4)
2/73 (2.7)
22/200 (11.0)
128/200 (64.0)
49/200 (24.5)
1/200 (0.5) 0.38
Marital status n/N (%)
Never married
Married or cohabitating
Separated, divorced or widowed
346/818 (42.3)
23/818 (2.8)
449/818 (54.9)
113/274 (41.2)
15/274 (5.1)
147/274 (53.7)
109/228 (47.8)
4/228 (1.8)
115/228 (50.4) 0.07
25/73 (34.3)
0/0 (0)
48/73 (65.8)
78/199 (39.2)
5/199 (2.5)
116/199 (58.3) 0.26
Number of live children n/N (%)
0
1
2-3
≥4
114/819 (13.9)
223/819 (27.2)
331/819 (40.4)
151/819 (18.4)
39/274 (14.7)
66/274 (25.1)
119/274 (41.9)
50/274 (18.4)
29/229 (12.7)
78/229 (34.1)
85/229 (37.1)
37/229 (16.2) 0.11
16/73 (21.9)
10/73 (13.7)
29/73 (39.7)
18/73 (24.7)
18/199 (9.1)
60/199 (30.2)
82/199 (41.2)
39/199 (19.6) 0.004
Workplace n/N (%)
Bar or nightclub
Home
Street
Hotel, guest house or other
580/820 (70.7)
163/820 (19.9)
54/820 (6.6)
23/820 (2.8)
179/274 (65.3)
63/274 (23.0)
23/274 (8.4)
9/274 (3.3)
167/229 (72.9)
44/229 (19.2)
10/229 (4.4)
8/229 (3.5) 0.17
52/73 (71.2)
14/73 (19.2)
4/73 (5.5)
3/73 (4.1)
149/200 (74.5)
33/200 (16.5)
16/200 (8.0)
2/200 (1.0) 0.31
Age started sex work mean
years (sd) | 23.9 (6.8) 23.7 (6.4) 22.6 (6.7) 0.07 25.6 (7.0) 25.3 (7.2) 0.73
Duration of sex work median
years (IQR)¥ 4 (2 – 8) 4 (2-8) 4 (2-7) 0.51 6 (3-10) 5 (3-8) 0.24
Number of partners median in
past week (IQR)¥ 3 (2 – 6) 3 (2-6) 3 (2-6) 0.59 3 (2-5) 3 (1-6) 0.80
Condom use at last sex with
client n/N (%) 661/819 (80.7) 210/273 (76.9) 195/229 (85.2) 0.02 58/73 (79.5) 161/200 (80.5) 0.85
Condom use (clients) n/N (%)
Never
Inconsistent
Always
17/820 (2.1)
285/820 (34.8)
518/820 (63.2)
11/274 (4.0)
102/274 (37.2)
161/274 (58.8)
3/229 (1.3)
78/229 (34.1)
148/229 (64.6) 0.12
1/73 (1.4)
28/73 (38.4)
44/73 (60.3)
1/200 (0.5)
62/200 (31.0)
137/200 (68.5) 0.37
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Table 2 Association of HIV status with cervical cytology and prevalence of high-risk HPV types in female
sex workers in Mombasa Kenya
Variable HIV-negative n/N(%) HIV-positive n/N (%) P
Risk ratio#
(95%CI)
Prevalence of high-risk HPV
Any high-risk HPV infection*
Type 16
Type 18
Type 31
Type 33
Type 35
Type 39
Type 45
Type 51
Type 52
Type 53
Type 56
Type 58
Type 59
Type 66
Type 68
Mean high-risk HPV types (sd)
N=503 229 (45.5)
56 (11.1)
34 (6.8)
31 (6.2)
1 (0.2)
39 (7.8)
20 (4.0)
18 (3.6)
32 (6.4)
38 (7.6)
35 (7.0)
24 (4.8)
21 (4.2)
43 (8.6)
37 (7.4)
2 (0.4)
0.8 (1.1)
N=273 200 (73.3)
66 (24.2)
51 (18.7)
33 (12.1)
3 (1.1)
49 (18.0)
36 (13.2)
21 (7.7)
39 (14.3)
70 (25.6)
56 (20.5)
39 (14.3)
15 (5.5)
36 (13.2)
40 (14.7)
6 (2.2)
1.8 (1.8)
<0.001
<0.001
<0.001
0.004
0.095
<0.001
<0.001
0.012
<0.001
<0.001
<0.001
<0.001
0.40
0.04
0.001
0.02
<0.001
1.7 (1.5-1.9)
2.4 (1.7-3.4)
2.9 (1.9-4.6)
2.0 (1.2-3.4)
4.3 (0.41-45.8)
2.7 (1.7-4.1)
4.2 (2.3-7.5)
2.3 (1.3-4.2)
2.5 (1.5-4.1)
3.7 (2.5-5.6)
3.0 (2.0-4.6)
2.9 (1.7-4.9)
1.4 (0.7-2.7)
1.7 (1.1-2.6)
2.1 (1.3-3.3)
5.5 (1.0-29.0)
Low risk HPV
Type 6
Type 67
N=503 13 (2.6)
87 (17.3)
N=273 10 (3.7)
84 (30.8)
0.40
<0.001
1.4 (0.63-3.3)
1.8 (1.4-2.4)
Viral load of high-risk HPV types
(n≥1 copy/cell; median (IQR))
Type 16
Type 18
Type 31
Type 33
Type 35
Type 39
Type 45
Type 51
Type 52
Type 53
Type 56
Type 58
Type 59
Type 66
Type 68
Total high-risk HPV viral load
38; 32.5 (4-472)
18; 12 (4-58)
22; 15 (3-572)
1; 204 (NA)
34; 118 (14-4882)
14; 13 (1-89)
14; 8 (2-24)
30; 43 (3-1738)
31; 12 (3-71)
27; 5 (2-14)
20; 112 (5.5-829)
12; 16 (4.5-67)
21; 27 (3-235)
22; 4 (2-794)
0; 0
48 (6-756)
52; 145 (12-3278)
31; 31 (6-718)
25; 208 (58-13 257)
3; 15 453 (251-45 601)
48; 302 (61-9969)
25; 106 (3-2600)
21; 49 (4-252)
37; 826 (34-43 983)
59; 76 (5-938)
47; 31 (1-288)
31; 219 (20-1511)
13; 7 (4-32)
20; 437 (20-3552)
35; 48 (7-1193)
1; 1; (NA)
811 (33-12 110)
0.016
0.23
0.02
0.18
0.11
0.06
0.04
0.02
0.05
0.14
0.39
0.81
0.04
0.07
-
<0.001
Cervical cytology (Pap smear)
Normal
ASC-US / ASC-H
LSIL
HSIL
Invasive carcinoma
N=503 461 (91.7)
8 (1.6)
21 (4.2)
12 (2.4)
1 (0.2)
N=269 196 (72.9)
6 (2.2)
54 (20.1)
13 (4.8)
0 (0) <0.001
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^Infection with HPV type 16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66 and 68 defined as high-risk HPV infection. *Any
detectable HPV viral load >0copies/cell considered diagnostic. #Age-adjusted risk ratio. LSIL low-grade intraepithelial lesion;
HSIL high-grade squamous intra-epithelial lesion; ASC-US atypical squamous cells of undetermined significance; ASC-H atypical
squamous cells: cannot exclude high-grade squamous intra-epithelial lesion. Median copies/cell are rounded to closest whole
number. Vari. Cat. Variable category
20
Table 3: Association of HIV and other covariates with high-risk HPV infection: multivariable logistic
regression analysis
Variable Unadjusted odds ratio(95%CI)
Adjusted odds ratio
(95%CI) P
Age
17-24
25-29
30-39
≥40
1.3 (0.80-2.0)
1.3 (0.83-2.1)
1.0 (0.66-1.7)
1.0
1.9 (1.1-3.2)
1.5 (0.92-2.5)
1.1 (0.69-1.7)
1.0
0.014
0.10
0.81
Have one or more children
No
Yes
1.0
1.5 (1.0-2.3)
1.0
2.0 (1.3-3.3) 0.003
Condom use with client at last sex
No
Yes
1.0
1.5 (1.0-2.1)
1.0
1.4 (0.96-2.1) 0.08
HIV infection
No
Yes
1.0
3.3 (2.4-4.5)
1.0
3.6 (2.6-5.1) <0.001
